3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neuroendocrine Tumors
7
Pheochromocytoma
2
Paraganglioma
2
Gastro-enteropancreatic neuroendocrine tumor
2
Vipoma
1
Thymus Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Meningioma
1
Insulinoma
1
Gastrinoma
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Interventions
pembrolizumab
12
Radiotherapy
9
avelumab
8
Nivolumab
8
cemiplimab
4
Radiation
4
Ipilimumab
4
poly ICLC
3
atezolizumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Cyclophosphamide
3
talimogene laherparepvec
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
aldesleukin
2
Interferon-beta
2
Immunoglobulin G
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
Carboplatin
2
Biopsy
2
veliparib
1
vatalanib
1
tremelimumab
1
tocilizumab
1
temsirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Merkel Cell
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn